Cargando…

Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance

Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Junru, Huang, Beihui, Gu, Jingli, Li, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055621/ https://www.ncbi.nlm.nih.gov/pubmed/36983594 http://dx.doi.org/10.3390/jpm13030412

Ejemplares similares

Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score
por: Chen, Yadong, et al.
Publicado: (2023)

Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing
por: Zhang, Bingqing, et al.
Publicado: (2019)

Health‐related quality of life of patients with multiple myeloma: A real‐world study in China
por: Li, Xiaozhe, et al.
Publicado: (2020)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study
por: Xiaozhe, Li, et al.
Publicado: (2022)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Multiple myeloma secondary to acute lymphoblastic leukemia: A case report
por: Hu, Tonglin, et al.
Publicado: (2019)

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
por: Huang, Beihui, et al.
Publicado: (2023)

Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma
por: Xu, Limei, et al.
Publicado: (2021)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review
por: Sinit, Ryan B., et al.
Publicado: (2019)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
por: Hus, I, et al.
Publicado: (2004)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report
por: Khan, Dr. Saqib Raza, et al.
Publicado: (2022)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Therapy-related B-lymphoblastic leukemia after multiple myeloma
por: Kallen, Michael E., et al.
Publicado: (2022)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
por: Khan, Abdullah M., et al.
Publicado: (2018)

Secondary acute lymphoblastic leukaemia in a multiple myeloma patient
por: Piszcz, Jaroslaw, et al.
Publicado: (2013)

Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma
por: Li, Ying, et al.
Publicado: (2016)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report
por: Li, Junxun, et al.
Publicado: (2016)

Corrigendum to “Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features”
por: Khan, Abdullah M., et al.
Publicado: (2019)

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma
por: Crosby, James, et al.
Publicado: (2022)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

A Case of Internal Carotid Artery Thrombosis associated with Thalidomide Administration in Multiple Myeloma
por: Grima, Maria Angela, et al.
Publicado: (2016)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nkafseimnq70om7b7r75t2l8d3